title: Pharmacological treatment of disabling tremor.
abstract: Tremor is often a disabling primary condition or secondary to another disorder. No universally effective pharmacological agent exists for the treatment of essential tremor, and patients differ greatly in their response to therapies, thus requiring individualised regimens. Deep brain stimulation is the best option for patients with disabling, drug-resistant essential tremor. Resting tremor in Parkinson's disease is usually not the primary disabling feature, and in most cases, levodopa/carbidopa is satisfactory for many years. Young Parkinson's patients with dominant, disabling tremor benefit from anticholinergics in addition to dopaminergic therapies. However, older Parkinson's patients with more disabling tremor may suffer from dose-dependent side effects, and deep brain stimulation should be considered. This article outlines the available pharmacological agents and treatment considerations for various disabling tremors, including essential tremor and Parkinson's disease.
authors.affiliation: Vanderbilt University, School of Medicine, Nashville, TN, USA.
authors.forename: Courtney R
authors.initials: CR
authors.lastname: Schadt
authors.forename: Ennis I
authors.initials: EI
authors.lastname: Duffis
authors.forename: P David
authors.initials: PD
authors.lastname: Charles
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D004421:Dystonia / Q000188:drug therapy*; D020329:Essential Tremor / Q000188:drug therapy*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D011324:Primidone / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D014202:Tremor / Q000188:drug therapy*
chemical_list: D011324:Primidone; D011433:Propranolol; D019274:Botulinum Toxins, Type A